Fagron NV 2018 AR2
The report highlights Fagron's strong performance in 2018, with turnover increasing by 8.8% to 471.7 million euros, driven by organic growth and strategic acquisitions like Humco in the United States. The company launched Fagron Genomics in Barcelona, specializing in innovative genetic tests, and initiated a rebranding process to support its vision in personalized medicine. In terms of sustainability, Fagron reported on non-financial aspects including quality and safety, diversity, human rights, and began identifying its greenhouse gas emissions in accordance with the GHG Protocol.
Company: Fagron NV
Sector: Manufacturing
Country: Belgium
Year: 2018
Type: AR2
Pages: 140
Back to company
Fagron NV
Annual Report
The report highlights Fagron's strong performance in 2018, with turnover increasing by 8.8% to 471.7 million euros, driven by organic growth and strategic acquisitions like Humco in the United States. The company launched Fagron Genomics in Barcelona, specializing in innovative genetic tests, and initiated a rebranding process to support its vision in personalized medicine. In terms of sustainability, Fagron reported on non-financial aspects including quality and safety, diversity, human rights, and began identifying its greenhouse gas emissions in accordance with the GHG Protocol.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees